


NATURAL PRODUCT COMMUNICATIONS

An International Journal for Communications and Reviews Covering all
Aspects of Natural Products Research



Volume 5. Issue 7. Pages 993-1160. 2010
ISSN 1934-578X (printed); ISSN 1555-9475 (online)
www.naturalproduct.us

EDITOR-IN-CHIEF**DR. PAWAN K AGRAWAL**

*Natural Product Inc.
7963, Anderson Park Lane,
Westerville, Ohio 43081, USA
agrawal@naturalproduct.us*

EDITORS**PROFESSOR ALESSANDRA BRACA**

*Dipartimento di Chimica Bioorganica e Biofarmacia,
Universita di Pisa,
via Bonanno 33, 56126 Pisa, Italy
braca@farm.unipi.it*

PROFESSOR DEAN GUO

*State Key Laboratory of Natural and Biomimetic Drugs,
School of Pharmaceutical Sciences,
Peking University,
Beijing 100083, China
gda5958@163.com*

PROFESSOR J. ALBERTO MARCO

*Departamento de Química Organica,
Universidade de Valencia,
E-46100 Burjassot, Valencia, Spain
alberto.marco@uv.es*

PROFESSOR YOSHIHIRO MIMAKI

*School of Pharmacy,
Tokyo University of Pharmacy and Life Sciences,
Horinouchi 1432-1, Hachioji, Tokyo 192-0392, Japan
mimakiy@ps.toyaku.ac.jp*

PROFESSOR STEPHEN G. PYNE

*Department of Chemistry
University of Wollongong
Wollongong, New South Wales, 2522, Australia
spyne@uow.edu.au*

PROFESSOR MANFRED G. REINECKE

*Department of Chemistry,
Texas Christian University,
Forts Worth, TX 76129, USA
m.reinecke@tcu.edu*

PROFESSOR WILLIAM N. SETZER

*Department of Chemistry
The University of Alabama in Huntsville
Huntsville, AL 35809, USA
wsetzer@chemistry.uah.edu*

PROFESSOR YASUHIRO TEZUKA

*Institute of Natural Medicine
Institute of Natural Medicine, University of Toyama,
2630-Sugitani, Toyama 930-0194, Japan
tezuka@inn.u-toyama.ac.jp*

PROFESSOR DAVID E. THURSTON

*Department of Pharmaceutical and Biological Chemistry,
The School of Pharmacy,
University of London, 29-39 Brunswick Square,
London WC1N 1AX, UK
david.thurston@pharmacy.ac.uk*

HONORARY EDITOR**PROFESSOR GERALD BLUNDEN**

*The School of Pharmacy & Biomedical Sciences,
University of Portsmouth,
Portsmouth, PO1 2DT U.K.
axuf64@dsl.pipex.com*

ADVISORY BOARD

Prof. Berhanu M. Abegaz
Gaborone, Botswana

Prof. Viqar Uddin Ahmad
Karachi, Pakistan

Prof. Øyvind M. Andersen
Bergen, Norway

Prof. Giovanni Appendino
Novara, Italy

Prof. Yoshinori Asakawa
Tokushima, Japan

Prof. Lee Banting
Portsmouth, U.K.

Prof. Julie Banerji
Kolkata, India

Prof. Anna R. Bilia
Florence, Italy

Prof. Maurizio Bruno
Palermo, Italy

Prof. Josep Coll
Barcelona, Spain

Prof. Geoffrey Cordell
Chicago, IL, USA

Prof. Cristina Gracia-Viguera
Murcia, Spain

Prof. Duvvuru Gunasekar
Tirupati, India

Prof. A.A. Leslie Gunatilaka
Tucson, AZ, USA

Prof. Kurt Hostettmann
Lausanne, Switzerland

Prof. Martin A. Iglesias Arteaga
Mexico, D. F, Mexico

Prof. Jerzy Jaroszewski
Copenhagen, Denmark

Prof. Leopold Jirovetz
Vienna, Austria

Prof. Teodoro Kaufman
Rosario, Argentina

Prof. Norbert De Kimpe
Gent, Belgium

Prof. Karsten Krohn
Paderborn, Germany

Prof. Hartmut Laatsch
Gottingen, Germany

Prof. Marie Lacaille-Dubois
Dijon, France

Prof. Shoen-Sheng Lee
Taipei, Taiwan

Prof. Francisco Macias
Cadiz, Spain

Prof. Imre Mathe
Szeged, Hungary

Prof. Joseph Michael
Johannesburg, South Africa

Prof. Ermino Murano
Trieste, Italy

Prof. M. Soledade C. Pedras
Saskatoon, Canada

Prof. Luc Pieters
Antwerp, Belgium

Prof. Om Prakash
Manhattan, KS, USA

Prof. Peter Proksch
Düsseldorf, Germany

Prof. Phila Raharivelomanana
Tahiti, French Polynesia

Prof. Satyajit Sarker
Wolverhampton, UK

Prof. Monique Simmonds
Richmond, UK

Prof. Valentin Stonik
Vladivostok, Russia

Prof. Winston F. Tinto
Barbados, West Indies

Prof. Karen Valant-Vetschera
Vienna, Austria

Prof. Peter G. Waterman
Lismore, Australia

INFORMATION FOR AUTHORS

Full details of how to submit a manuscript for publication in Natural Product Communications are given in Information for Authors on our Web site <http://www.naturalproduct.us>.

Authors may reproduce/republish portions of their published contribution without seeking permission from NPC, provided that any such republication is accompanied by an acknowledgment (original citation)-Reproduced by permission of Natural Product Communications. Any unauthorized reproduction, transmission or storage may result in either civil or criminal liability.

The publication of each of the articles contained herein is protected by copyright. Except as allowed under national "fair use" laws, copying is not permitted by any means or for any purpose, such as for distribution to any third party (whether by sale, loan, gift, or otherwise); as agent (express or implied) of any third party; for purposes of advertising or promotion; or to create collective or derivative works. Such permission requests, or other inquiries, should be addressed to the Natural Product Inc. (NPI). A photocopy license is available from the NPI for institutional subscribers that need to make multiple copies of single articles for internal study or research purposes.

To Subscribe: Natural Product Communications is a journal published monthly. 2010 subscription price: US\$1,695 (Print, ISSN# 1934-578X); US\$1,695 (Web edition, ISSN# 1555-9475); US\$2,095 (Print + single site online); US\$595 (Personal online). Orders should be addressed to Subscription Department, Natural Product Communications, Natural Product Inc., 7963 Anderson Park Lane, Westerville, Ohio 43081, USA. Subscriptions are renewed on an annual basis. Claims for nonreceipt of issues will be honored if made within three months of publication of the issue. All issues are dispatched by airmail throughout the world, excluding the USA and Canada.

Antifungal Activity of Saponin-rich Extracts of *Phytolacca dioica* and of the Sapogenins Obtained through Hydrolysis

Melina Di Liberto^a, Laura Svetaz^a, Ricardo L. E. Furlán^a, Susana A. Zacchino^a,
Carla Delporte^b, Marco A. Novoa^c, Marcelo Asencio^c and Bruce K. Cassels^{d*}

^aFarmacognosia, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Suipacha 531, Rosario 2000, Argentina

^bLaboratorio de Productos Naturales, Departamento de Química Farmacológica y Toxicológica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Casilla 233, Santiago-1, Chile

^cLaboratorio de Química Bioinorgánica y de Productos Naturales, Facultad de Ecología, Matemáticas y el Medio Ambiente, Universidad Tecnológica Metropolitana, J.P. Alessandri 1242, Ñuñoa, Santiago, Chile

^dDepartment of Chemistry, Faculty of Sciences, University of Chile, Las Palmeras 3425, Ñuñoa, Santiago, Chile

bcassels@uchile.cl

Received: March 18th, 2010; Accepted: May 20th, 2010

A saponin-rich extract of *Phytolacca dioica* L. berries, its acid hydrolysate, and its major aglycone, phytolaccagenin, were assayed for antifungal activity against ATCC standard cultures of *Candida albicans* and *Cryptococcus neoformans*, and against clinical isolates of these fungi. The activity of the extract was either low or negligible, but the hydrolysate, containing the sapogenins, including phytolaccagenin, and also pure phytolaccagenin, showed promising antifungal potency. Hydrolysis of a natural product extract is shown to be a useful modification leading to improved bioactivity.

Keywords: Saponins, phytolaccagenin, antifungal activity.

Invasive fungal infections are a major cause of morbidity and mortality in immunocompromised patients [1,2]. Although there appears to be a plentiful armamentarium of antifungal drugs in clinical use, in fact only a modest number of drugs are available [3]. In addition, they show undesirable toxicity, and either facilitate recurrence or lead to the development of resistance due, in part, to the intensive prophylactic use of antifungal drugs [4]. There is, therefore, a clear and urgent need for the discovery of new alternative compounds for antifungal therapy [5]. Plants provide unlimited opportunities for the isolation of new antifungal products because of their unmatched chemical diversity [6,7]. In fact, numerous antifungal compounds have been isolated from them [8-13], including some natural saponins that have demonstrated either strong or at least modest activity [14-17].

The plant genus *Phytolacca* is well known as a source of triterpenoid saponins containing aglycones with oleanolic acid-derived structures (oleanolic [18], phytolaccagenic [19,20], serjanic [21], jaligonin [22] and esculentagenic [23] acids, hederagenin [24], bayogenin




Figure 1: Structures of phytolaccagenic acid (R = H) and phytolaccagenin (R = OH).

[25] and phytolaccagenin [21,25,26]). Among the species of this genus, *P. dioica* L. has been shown to contain the bidesmosidic saponins esculentoside S and esculentoside L₁ [27], which are glycosides of phytolaccagenic acid and phytolaccagenin, respectively (Figure 1), the major sapogenins of this plant [28].

Regarding the phytochemistry of the genus *Phytolacca*, both phytolaccoside B {3-O-(β-D-xylopyranosyl)-phytolaccagenin = phytolaccasaponin G [29] = esculentoside B [30]} isolated from *P. americana*

[29,31-33], *P. esculenta* [22,31], *P. dodecandra*, *P. acinosa* [29] and *P. tetramera* [26], and phytolaccoside E {3-*O*-(β -D-glucopyranosyl-(1 \rightarrow 4)- β -D-xylopyranosyl)-phytolaccagenin = phytolaccasaponin E = esculentoside A} produced by *P. americana* [33,34] and *P. esculenta* [31], showed activity against the plant pathogen *Cladosporium herbarum* [34], and against a panel of human opportunistic yeasts and molds [26]. In addition, recent studies have demonstrated that phytolaccoside B alters the morphology of the fungal cell wall by increasing the amount of chitin and thus causing the death of the fungus [35].

It is worth noting that the antifungal activities exhibited by saponins of the genus *Phytolacca* might be useful for the development of antifungal drugs and agrochemicals. Nevertheless, although it is clear that saponins represent an interesting platform for the development of antifungal compounds, it is also well known that their complex chemical structures demand sophisticated techniques for their isolation and structure elucidation [16]. Since it has been reported recently that the chemical transformation of natural product mixtures to generate chemically engineered extracts can be an entry point to discover bioactive compounds [37,38], the saponin-rich *n*-butanol extract of *P. dioica* berries was subjected to acid hydrolysis. This is expected to produce a saponin-enriched mixture, reducing the molecular weight and increasing the average lipophilicity of its constituents. Consequently, the generated compounds should have better chances of entering the fungal membrane, as compared with the original natural components, and exert their effects either there or in the cytoplasm.

The *n*-butanol extract (BE) of *P. dioica* berries, as well as its acid hydrolysate (BH), were tested against *Candida albicans* ATCC 10231 and *Cryptococcus neoformans* ATCC 32264, using the microbroth dilution assay. The relevance of these fungi to the epidemiology of fungal infections is well known. Candidiasis is now the fourth most prevalent blood-stream infection in immunocompromised hosts, *C. albicans* representing more than 60% of isolates from clinical infections [2]. In turn, *C. neoformans* remains an important life-threatening complication, particularly for patients who have undergone transplantation of solid organs, and, therefore, new compounds acting against this fungus are highly welcome [39].

Results showed that BE did not display any activity at concentrations up to 250 μ g/mL (Table 1, line 1), but, in contrast, BH showed promising antifungal activities against the same yeasts.

Table 1: Minimum inhibitory concentrations of the *P. dioica n*-butanol extract (BE) and its acid hydrolysis mixture against standard cultures of *C. albicans* and *C. neoformans*. In addition, MIC values of phytolaccagenin (PG) and two reference antifungals are included.

Sample	MIC <i>C. albicans</i> ATCC 10231 (μ g/mL)	MIC <i>C. neoformans</i> ATCC 32264 (μ g/mL)
BE	> 250	> 250
BH	62.5	31.2
PG	62.5	15.6
Amphotericin B	0.25	0.25
Ketoconazole	0.50	0.25

Both mixtures were subjected to TLC (*n*-hexane: ethyl acetate, 30:70), and bioautographed using *C. neoformans* ATCC 32264. This qualitative bioassay showed again that BE did not have any antifungal component and instead, BH inhibited the fungal growth in a zone that could be ascribed to only one compound. The bioassay-guided fractionation of BH led to the isolation and characterization of phytolaccagenin (PG) as the compound responsible for the antifungal activity. In microdilution assays, PG showed similar antifungal behavior to BH (MIC = 62.5 μ g/mL) against *C. albicans* and slightly better activity than the hydrolysate against *C. neoformans* (MIC 15.6 and 31.2 μ g/mL respectively) (Table 1).

In order to get a closer look at the differences in antifungal properties among BE, BH, and PG, we assayed the three samples in a new panel consisting of six clinical isolates of *C. albicans* and ten of *C. neoformans*, obtained from immunocompromised patients.

The MIC values of the three samples were determined against this extended panel by using three endpoints MIC₁₀₀, MIC₈₀ and MIC₅₀ (the minimum concentration of compounds that inhibits 100, 80 and 50 % of growth, respectively) (Table 2). The application of less stringent endpoints, such as MIC₈₀ and MIC₅₀, has been shown consistently to represent the *in vitro* activity of compounds [40] and often provides a better correlation with other measurements of antifungal activity [41].

Results showed that BE was almost inactive (MIC \geq 250 μ g/mL) against the whole panel listed in table 2. In contrast, BH and PG showed activity against all strains of the panel. Regarding the behavior of both BH and PG against *C. albicans*, they showed similar MIC₁₀₀ (62.5 μ g/mL for both in all strains tested), MIC₈₀ (range 31.2 - 62.5 for BH and 62.5 μ g/mL for PG) and MIC₅₀ values (31.2 - 62.5 μ g/mL) for the hydrolysate and the genin respectively. In turn, results of BH and PG against *C. neoformans* showed again that both samples possessed similar activity, but with the difference that this fungal species was more sensitive to BH and PG (MIC range observed: 15.6 - 62.5 μ g/mL) than *C. albicans*.

Table 2: Comparative minimum inhibitory concentrations (MIC₁₀₀, MIC₈₀ and MIC₅₀) of the *Phytolacca dioica* *n*-butanol extract (BE), its hydrolysate (BH), and phytolaccagenin (PG) against clinical isolates of *Candida albicans* (*Ca*) and *Cryptococcus neoformans* (*Cn*). For the sake of comparison, the MIC₁₀₀ of both samples against ATCC standard cultures and those of amphotericin B (Amph B) against the clinical isolates are included.^a NA = not active (MIC₁₀₀ > 250 µg/mL).

		BE	MIC ₁₀₀		MIC ₈₀		MIC ₅₀		MIC ₁₀₀
			BH	PG	BH	PG	BH	PG	Amph B
<i>Ca</i>	ATCC10231	NA ^a	62.5	62.5					
<i>Ca</i>	C 125	NA	62.5	62.5	62.5	62.5	31.2	62.5	0.78
<i>Ca</i>	C 126	NA	62.5	62.5	31.2	62.5	31.2	62.5	1.56
<i>Ca</i>	C 127	250	62.5	62.5	62.5	62.5	31.2	31.2	0.78
<i>Ca</i>	C 128	NA	62.5	62.5	31.2	62.5	31.2	62.5	1.56
<i>Ca</i>	C 129	NA	62.5	62.5	62.5	62.5	62.5	31.2	0.78
<i>Ca</i>	C 130	250	62.5	62.5	31.2	62.5	31.2	31.2	0.39
<i>Cn</i>	ATCC 32264	NA	31.2	15.6					
<i>Cn</i>	IM 983040	NA	62.5	31.2	62.5	31.2	31.2	15.6	0.25
<i>Cn</i>	IM 972724	250	62.5	62.5	62.5	31.2	31.2	15.6	0.13
<i>Cn</i>	IM 042074	NA	62.5	62.5	62.5	31.2	31.2	15.6	0.06
<i>Cn</i>	IM 983036	NA	62.5	62.5	62.5	31.2	15.6	15.6	0.25
<i>Cn</i>	IM 00319	NA	62.5	62.5	62.5	31.2	62.5	31.2	0.13
<i>Cn</i>	IM 972751	NA	62.5	31.2	31.2	31.2	15.6	15.6	0.25
<i>Cn</i>	IM 031631	NA	62.5	31.2	31.2	31.2	15.6	15.6	0.25
<i>Cn</i>	IM 031706	250	62.5	31.2	31.2	31.2	15.6	15.6	0.13
<i>Cn</i>	IM 961951	NA	62.5	62.5	62.5	31.2	31.2	15.6	0.25
<i>Cn</i>	IM 052470	NA	62.5	31.2	62.5	31.2	31.2	15.6	0.06

In conclusion, (a) acid hydrolysis of the either inactive or marginally active *n*-butanol extract of *P. dioica* berries (BE) led to a mixture containing sapogenins (BH, where phytolaccagenin and phytolaccagenic acid are presumably the major constituents [28]), which was not only more active against the standard fungal strains, but also against the clinical isolates of *C. albicans* and *C. neoformans*; (b) phytolaccagenin was responsible for practically all the activity of BH, as the difference observed in the activity of both samples for all isolates was in no case more than one two-fold dilution; (c) *C. neoformans* proved to be more sensitive than *C. albicans* to the *P. dioica* sapogenins and to pure phytolaccagenin.

This work demonstrates that the hydrolysis of a saponin-rich extract led to a new mixture with stronger and promising activities that could open new avenues for the discovery of novel antifungal agents. In addition, the work provides new evidence that the chemical modification of a natural product extract can lead to mixtures with improved properties that can be used as sources of bioactive compounds [37].

Experimental

Plant material and chemistry: *Phytolacca dioica* L. (Phytolaccaceae) berries, collected at the Faculty of Sciences campus of the University of Chile in Santiago in February 2008 (voucher specimen SQF 22461, Herbarium of the Faculty of Chemical and Pharmaceutical Sciences) were dried, ground and extracted sequentially with hexanes, CH₂Cl₂ and MeOH. From the concentrated MeOH extract abundant crystals of sucrose precipitated and were removed. Dilution with water, extraction with *n*-BuOH, and

concentration to dryness afforded BE. This was heated under reflux for 3 h with 3 M HCl, which on cooling deposited a brown solid (BH). BH was chromatographed on silica gel to obtain phytolaccagenin in sufficient quantity for the biological assays. The purity (> 95%) and identity of phytolaccagenin were established by TLC and HPLC, and by one- and two-dimensional ¹H and ¹³C NMR spectroscopy.

Microorganisms and media: For the microbroth dilution method, standard strains (*C. albicans* ATCC 10231, *C. neoformans* ATCC 32264) were obtained from the American Type Culture Collection, Rockville, MD, USA. Six clinical isolates of *C. albicans* and 10 of *C. neoformans* were kindly provided by the Centro de Referencia en Micología (C, CEREMIC, Rosario) and the Malbrán Institute (IM, Av. Vélez Sarsfield 563, Buenos Aires). Their voucher numbers are presented in Table 2. They were grown on Sabouraud-chloramphenicol agar slants for 48 h at 30°C, maintained on slopes of Sabouraud-dextrose agar (SDA, Oxoid), and sub-cultured every 15 days to avoid pleomorphic transformations. Inocula were obtained according to reported procedures [40,41] and adjusted to 1-5 × 10³ cells/spores with colony forming units (CFU/mL).

Antifungal susceptibility tests: Minimum inhibitory concentrations (MIC) of BE, BH, and PG were determined by using broth microdilution techniques according to the guidelines of the CSLI (formerly NCCLS) [40]. MIC values were determined in RPMI-1640 (Sigma, St. Louis, MO, USA) buffered to pH 7.0 with MOPS. Microtiter trays were incubated at 30°C in

a moist, dark chamber, and MICs were recorded at 48 h. For the assay, stock solutions of either the extract or pure compound were diluted with RPMI from 1000 or 250, respectively, to 0.98 µg/mL (final volume = 100 µL) and final DMSO concentration ≤ 2%. Inoculum suspension (100 µL) was added to each well with the exception of the sterility control, where sterile water was added instead. Ketoconazole and amphotericin B (Sigma Chemical Co., St. Louis, MO, USA) were used as positive controls. Endpoints were defined as the lowest concentration of either extract or compound resulting in total inhibition (MIC₁₀₀) of visually observed growth compared with the growth in the control wells containing no test compound. To determine the minimal concentrations causing 80 or 50% inhibition of fungal growth (MIC₈₀ or MIC₅₀), the percentages of inhibition of the clinical isolates of *C. albicans* and *C. neoformans* were determined at 7 concentrations: 250, 125, 62.5, 31.25, 15.62, 7.8, and 3.9 µg/mL, for BH and PG). The tests were performed in 96-well microplates. Sample test wells (STW) were prepared with stock solutions of BH or PG in DMSO (≤ 2%), diluted with RPMI-1640 to each final concentration (100 µL). An inoculum suspension (100 µL) was added to each well. A growth control well (GCW) containing medium, inoculum, and the same amount of DMSO used in the STW, but sample-free) and a sterility control well (SCW) (sample, medium and sterile water instead of inoculum) were included for each strain tested. Microtiter trays were incubated for 48 h in a moist, dark chamber at 30°C. Microplates were read in a VERSA Max microplate reader (Molecular Devices, Sunnyvale, CA, USA). Amphotericin B was used as a positive control. Tests were performed in

triplicate. Reduction of fungal growth due to each sample concentration was calculated as follows:

$$\% \text{ inhibition} = 100 - (\text{OD}_{405} \text{ STW} - \text{OD}_{405} \text{ SCW}) / (\text{OD}_{405} \text{ GCW} - \text{OD}_{405} \text{ SCW}).$$

From these data, MIC₈₀ and MIC₅₀ were determined. They were defined as the lowest concentration of either BH or PG that showed 80% or 50% reduction of growth, respectively.

Bioautography: BE, BH and PG were analyzed in duplicate by TLC. One of the plates was sprayed with anisaldehyde/sulfuric acid reagent followed by heating at 100°C for 5-10 min to visualize the spots [42]. The other plate was bioautographed as follows: warm agar-Sabouraud medium with 0.02% phenol red (1 mL/cm²) containing a *C. neoformans* ATCC 32264 inoculum of 1-4 × 10⁵ cells/mL, quantified in accordance with reported procedures [43,44], was distributed over the developed TLC plate. After solidification of the medium, the plate was put into a sterile Petri dish, covered, and incubated overnight at 28°C. Subsequently, the bioautogram was sprayed with an aqueous solution (1 mg/mL) of MTT (methylthiazolyltetrazolium chloride) and incubated for 2 h at 28°C. Yellow inhibition zones appeared against a dark brown background [44].

Acknowledgments – This work was funded by grants from FONDECYT (Chile) 1080174, ICM (Chile) P05-001-F, ANPCyT (Argentina) PICT995, and UNR (Argentina) BIO 133.

References

- [1] Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, Walsh TJ, Maertens J, Patterson TF, Perfect JR, Dupont B, Wingard JR, Calandra T, Kauffman CA, Graybill JR, Baden LR, Pappas PG, Bennett JE, Kontoyiannis DP, Cordonnier C, Viviani MA, Bille J, Almyroudis NG, Wheat LJ, Graninger W, Bow EJ, Holland SM, Kullberg BJ, Dismukes WE, De Pauw BE. (2008) Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. *Clinical and Infectious Diseases*, **47**, 674-683.
- [2] Pfaller MA, Diekema DJ. (2007) Epidemiology of invasive candidiasis: a persistent public health problem. *Clinical and Microbiology Reviews*, **20**, 133-163.
- [3] Mathew B, Nath M. (2009) Recent approaches to antifungal therapy for invasive mycoses. *ChemMedChem*, **4**, 310-323.
- [4] Mukherjee PK, Leidich SD, Isham N, Leitner I, Ryder NS, Ghannoum MA. (2003) Clinical *Trichophyton rubrum* strain exhibiting primary resistance to terbinafine. *Antimicrobial Agents and Chemotherapy*, **47**, 82-86.
- [5] Patterson TF. (2005) Advances and challenges in management of invasive mycoses. *Lancet*, **366**, 1013-1025.
- [6] Maregesi S, Pieters L, Ngassapa O, Apers S, Vigerhoets R, Cos P, Vanden Berghe D, Vlietink A. (2008) Screening of some Tanzanian medicinal plants from Bunda district for antibacterial, antifungal and antiviral activities. *Journal of Ethnopharmacology*, **119**, 58-66.
- [7] Cos P, Vlietink A, Vanden Berghe D, Maes L. (2006) Anti-infective potential of natural products: how to develop a stronger *in vitro* "proof-of-concept". *Journal of Ethnopharmacology*, **106**, 290-302.
- [8] Agrawal SK, Singh S, Verma S, Kumar S. (2000) Antifungal activity of anthraquinone derivatives from *Rheum emodi*. *Journal of Ethnopharmacology*, **72**, 43-46.

- [9] Danelutte AP, Lagoa JH, Young MC, Kato MJ. (2003) Antifungal flavanones and prenylated hydroquinones from *Piper crassinervium* Kunth. *Phytochemistry*, **64**, 555-559.
- [10] Malheiros A, Cechinel Filho V, Schmitt C, Yunes R, Escalante A, Svetaz L, Zacchino S, Delle Monache F. (2005) Antifungal activity of drimane sesquiterpenes from *Drymis brasiliensis* using bioassay-guided fractionation. *Journal of Pharmacy and Pharmaceutical Sciences*, **8**, 335-339.
- [11] Stein A, Alvarez S, Avancini C, Zacchino S, von Poser G. (2006) Antifungal activity of some coumarins obtained from species of *Pterocaulon* (Asteraceae). *Journal of Ethnopharmacology*, **107**, 95-98.
- [12] Agüero M, Alvarez S, Luna L, Feresin G, Derita M, Tapia A, Zacchino S. (2007) Antifungal activity of *Zuccagnia punctata* Cav. Evidences for the mechanism of action. *Planta Medica*, **73**, 1074-1080.
- [13] Pacciaroni A, Gette M, Derita M, Ariza Espinar L, Gil R, Zacchino S, Silva G. (2008) Antifungal activity of *Heterothalamus alienus* metabolites. *Phytotherapy Research*, **22**, 524-528.
- [14] Oleszek AW. (2000) Saponins. In: *Natural Food Antimicrobial Systems*, Naidu AS (Ed.). CRC Press, London, 295-324.
- [15] Sparg S, Light M, Van Staden J. (2004) Biological activities and distribution of plant saponins. *Journal of Ethnopharmacology*, **94**, 239-243.
- [16] Francis G, Kerem Z, Makkar HPS. (2002) The biological action of saponins in animal systems: a review. *The British Journal of Nutrition*, **88**, 587-605.
- [17] Kim N, Desjardins A, Wu C, Kinghorn D. (1999) Activity of triterpenoid glycosides from the root bark of *Mussaenda macrophylla* against two oral pathogens. *Journal of Natural Products*, **62**, 1379-1384.
- [18] Parkhurst R, Thomas D, Skinner W. (1973) Molluscidal saponins of *Phytolacca dodecandra*: oleanoglycotoxin. *Phytochemistry*, **12**, 1437-1442.
- [19] Yi Y. (1991) A triterpenoid saponin from *Phytolacca esculenta*. *Phytochemistry*, **30**, 2552-2554.
- [20] Yi Y. (1991) A triterpenoid and its saponin from *Phytolacca esculenta*. *Phytochemistry*, **30**, 4179-4181.
- [21] Haraguchi M, Motidome M, Gottlieb O. (1988) Chemical study of the saponins of *Phytolacca thyriflora*. *Acta Amazonica* **18**, 443-448.
- [22] Woo W, Kang S. (1977) The structure of phytolaccoside G. *Journal of the Pharmaceutical Society of Korea*, **21**, 159-162.
- [23] Yi Y, Dai F. (1991) A new triterpenoid and its glycoside from *Phytolacca esculenta*. *Planta Medica*, **57**, 162-164.
- [24] Slacanin I, Marston A, Hostettmann K. (1988) High-performance liquid chromatographic determination of molluscicidal saponins from *Phytolacca dodecandra*. *Journal of Chromatography*, **448**, 265-274.
- [25] Yi Y. (1992) Two new saponins from the roots of *Phytolacca esculenta*. *Planta Medica*, **58**, 89-101.
- [26] Escalante AM, Santecchia CB, López SN, Gattuso MA, Gutiérrez Ravelo A, Delle Monache F, González Sierra M, Zacchino SA (2002) Isolation of antifungal saponins from *Phytolacca tetramera*, an Argentinean species in critical risk. *Journal of Ethnopharmacology*, **82**, 29-34.
- [27] Soliman HSM, Simon A, Tóth G, Duddeck H (2001) Identification and structure determination of four triterpene saponins from some Middle-East plants. *Magnetic Resonance in Chemistry*, **39**, 567-576.
- [28] Santander-Andrade P. (1978) Fruit saponins of *Phytolacca dioica* (ombú). MSc Thesis, Faculty of Sciences, University of Chile.
- [29] Spengel SM, Luterbacher S, Schaffner W. (1995) New aspects on the chemotaxonomy of *Phytolacca dodecandra* with regard to the isolation of phytolaccagenin, phytolaccagenic acid and their glycosides. *Planta Medica*, **61**, 385-386.
- [30] Strauss A, Spengel SM, Schaffner W. (1995) Saponins from root cultures of *Phytolacca acinosa*. *Phytochemistry*, **38**, 861-865.
- [31] Woo WS, Kang SS. (1975) The occurrence and chemistry of *Phytolacca* triterpenoids. *Journal of the Pharmaceutical Society of Korea*, **19**, 189-208.
- [32] Woo WS, Kang SS. (1976) Phytolaccoside B: Triterpene glucoside from *Phytolacca americana*. *Phytochemistry*, **15**, 1315-1317.
- [33] Suga Y, Maruyama Y, Kawanishi S, Shoji J. (1978) Studies on the constituents of Phytolaccaceae plants. I. On the structures of phytolaccasaponin B, E, and G from the roots of *Phytolacca americana*. *Chemical and Pharmaceutical Bulletin*, **26**, 520-525.
- [34] Kobayashi A, Hagihara K, Kajiyama S, Kanzaki H, Kawazu K. (1995) Antifungal compounds induced in the dual culture with *Phytolacca americana* callus and *Botrytis fabae*. *Zeitschrift für Naturforschung C*, **50**, 398-402.
- [35] Escalante A, Gattuso A, Pérez P, Zacchino S. (2008) Evidence for the mechanism of action of the antifungal phytolaccoside B isolated from *Phytolacca tetramera* Hauman. *Journal of Natural Products*, **71**, 1720-1725.
- [36] Peláez F, Cabellos A, Platas G, Díez M, González del Val A, Basilio A, Martán I, Vicente F, Bills G, Giacobbe R, Schwartz E, Onishi J, Mainz M, Abruzzo G, Flattery A, Kong L, Kurtz M. (2000) The discovery of enfumafungin, a novel antifungal compound produced by an endophytic *Hormonema* species, biological activity and taxonomy of the producing organisms. *Systematic and Applied Microbiology*, **23**, 333-343.
- [37] López SN, Ramallo IA, González Sierra M, Zacchino SA, Furlán RLE. (2007) Chemically engineered extracts as an alternative source of bioactive natural product-like compounds. *Proceedings of the National Academy of Sciences USA*, **104**, 441-444.
- [38] Salazar MO, Ramallo IA, Micheloni O, González Sierra M, Furlán RLE. (2009) Chemically engineered extracts: bioactivity alteration through sulfonylation. *Bioorganic and Medicinal Chemistry Letters*, **19**, 5067-5070.

- [39] Singh N. (2003) Treatment of opportunistic mycoses: how long is long enough? *The Lancet Infectious Diseases*, **3**, 703-708.
- [40] Clinical and Laboratory Standards Institute (CLSI), formerly National Committee for Clinical Laboratory Standards (NCCLS). (2002) Reference method for broth dilution antifungal susceptibility testing of yeasts and filamentous fungi, approved standard. Vol 22, 2nd ed. NCCLS, Wayne, PA, 1-29.
- [41] Ernst E, Roling E, Petzold R, Keele D, Klepser M. (2002) *In vitro* activity of micafungin (FK-463) against *Candida* spp.: microdilution, time-kill, and postantifungal-effect studies. *Antimicrobial Agents and Chemotherapy*, **46**, 3846-3853.
- [42] Wagner H, Bladt S. (1996) *Plant Drug Analysis. A Thin Layer Chromatography Atlas*, 2nd ed. Springer Verlag (Berlin), 305-326; 335-340; 359.
- [43] Wright LR, Scott EM, Gorman SP. (1983) The sensitivity of mycelium, arthrospores, and microconidia of *Trichophyton mentagrophytes* to imidazoles determined by *in vitro* tests. *Journal of Antimicrobial Chemotherapy*, **12**, 317-327.
- [44] Rahalison L, Hamburger M, Hostettmann K, Monod M, Frenk E. (1991) A bioautographic agar overlay method for the detection of antifungal compounds from higher plants. *Phytochemical Analysis*, **2**, 199-203.

Coumarins from <i>Seseli hartvigii</i> Lin Zhang, Alev Tosun, Masaki Baba, Yoshihito Okada, Lijun Wu and Toru Okuyama	1067
Spartinoxide, a New Enantiomer of A82775C with Inhibitory Activity Toward HLE from the Marine-derived Fungus <i>Phaeosphaeria spartinae</i> Mahmoud Fahmi Elsebai, Stefan Kehraus, Michael Gütschow and Gabriele M. König	1071
The First Total Synthesis of Aspergillusol A, an α-Glucosidase Inhibitor Nisar Ullah and Shamsuddeen A. Haladu	1077
The Effect of a Phytosphingosine-like Substance Isolated from <i>Asterina pectinifera</i> on Involucrin Expression in Mite Antigen-Stimulated HaCaT Cells Gui Hyang Choi, Fazli Wahid and You Young Kim	1081
Chemical Composition of Fatty Acid and Unsaponifiable Fractions of Leaves, Stems and Roots of <i>Arbutus unedo</i> and <i>in vitro</i> Antimicrobial Activity of Unsaponifiable Extracts Mohamed Amine Dib, Julien Paolini, Mourad Bendahou, Laurent Varesi, Hocine Allali, Jean-Marie Desjobert, Boufeldja Tabti and Jean Costa	1085
Poly[3-(3,4-dihydroxyphenyl)glyceric Acid] from <i>Anchusa italica</i> Roots Vakhtang Barbakadze, Lali Gogilashvili, Lela Amiranashvili, Maia Merlani, Karen Mulkijanyan, Manana Churadze, Antonio Salgado and Bezhan Chankvetadze	1091
New Metabolite from <i>Viburnum dilatatum</i> Bin Wu, Xing Zeng and Yufeng Zhang	1097
Two New Glycosides from <i>Conyza bonariensis</i> Aqib Zahoor, Imran Nafees Siddiqui, Afsar Khan, Viqar Uddin Ahmad, Amir Ahmed, Zahid Hassan, Saleha Suleman Khan and Shazia Iqbal	1099
K⁺_{ATP} Channels-Independent Analgesic Action of <i>Crotalus durissus cumanensis</i> venom Ticiana Praciano Pereira, Adriana Rolim Campos, Luzia Kalyne A. M. Leal, Taiana Magalhães Pierdoná, Marcos H. Toyama, and Helena Serra Azul Monteiro and Alice Maria Costa Martins	1103
Isothymol in Ajowan Essential Oil Chahrazed Bekhechi, Jean Brice Boti, Fewzia Atik Bekkara, Djamel Eddine Abdelouahid, Joseph Casanova and Félix Tomi	1107
GC-MS Analysis of the Essential Oils of Ripe Fruits, Roots and Flowering Aerial Parts of <i>Elaeoselinum asclepium</i> subsp. <i>meoides</i> growing in Sicily Ammar Bader, Pier Luigi Cioni and Guido Flamini	1111
Chemical Composition of the Essential Oil of Leaves and Roots of <i>Ottoa oenanthoides</i> (Apiaceae) from Mérida, Venezuela Janne Rojas, Alexis Buitrago, Luis B. Rojas, Antonio Morales and Shirley Baldovino	1115
Volatile Profiles of <i>Artemisia alba</i> from Contrasting Serpentine and Calcareous Habitats Niko Radulović and Polina Blagojević	1117
Volatile Constituents of Two Rare Subspecies of <i>Thymus praecox</i> Danijela Vidic, Sanja Čavar, Marija Edita Šolić and Milka Maksimović	1123
Antiproliferative and Cytotoxic Effects on Malignant Melanoma Cells of Essential Oils from the Aerial Parts of <i>Genista sessilifolia</i> and <i>G. tinctoria</i> Daniela Rigano, Alessandra Russo, Carmen Formisano, Venera Cardile and Felice Senatore	1127
Chemical Composition and Antibacterial Activity of the Essential Oil of <i>Retrophyllum rospigliosii</i> Fruits from Colombia Clara E. Quijano-Celis, Mauricio Gaviria, Consuelo Vanegas-López, Ina Ontiveros, Leonardo Echeverri, Gustavo Morales and Jorge A. Pino	1133
Essential Oil Composition and Insecticidal Activity of <i>Blumea perrottetiana</i> Growing in Southwestern Nigeria Moses S. Owolabi, Labunmi Lajide, Heather E. Villanueva and William N. Setzer	1135
Chemical Composition, Antibacterial and Antioxidant Activity of the Essential Oil of <i>Bupleurum longiradiatum</i> Baojun Shi, Wei Liu, Shao-peng Wei and Wen-jun Wu	1139
Composition and Antimicrobial and Anti-wood-decay Fungal Activities of the Leaf Essential Oils of <i>Machilus pseudolongifolia</i> from Taiwan Chen-Lung Ho, Pei-Chun Liao, Kuang-Ping Hsu, Eugene I-Chen Wang, Wei-Chih Dong and Yu-Chang Su	1143
Key Enzymes of Triterpenoid Saponin Biosynthesis and the Induction of Their Activities and Gene Expressions in Plants Chang Ling Zhao, Xiu Ming Cui, Yan Ping Chen and Quan Liang	1147

Natural Product Communications

2010

Volume 5, Number 7

Contents

<u>Original Paper</u>	<u>Page</u>
A DFT Analysis of Thermal Decomposition Reactions Important to Natural Products William N. Setzer	993
Novel Terpenoids from the New Zealand Liverworts <i>Jamesoniella colorata</i> and <i>Bazzania novae-zelandiae</i> Masao Toyota, Ikuko Omatsu, Fumi Sakata, John Braggins and Yoshinori Asakawa	999
Two New C₂₀-Diterpenoid Alkaloids from <i>Delphinium anthriscifolium</i> var. <i>savatieri</i> Xiao-Yu Liu, Lei Song, Qiao-Hong Chen, and Feng-Peng Wang	1005
Cytotoxic Activity of Quassinoids from <i>Eurycoma longifolia</i> Katsunori Miyake, Feng Li, Yasuhiro Tezuka, Suresh Awale and Shigetoshi Kadota	1009
Antifungal Activity of Saponin-rich Extracts of <i>Phytolacca dioica</i> and of the Sapogenins Obtained through Hydrolysis Melina Di Liberto, Laura Svetaz, Ricardo L. E. Furlán, Susana A. Zacchino, Carla Delporte, Marco A. Novoa, Marcelo Asencio and Bruce K. Cassels	1013
New Lupane-type Triterpenoid Saponins from Leaves of <i>Oplopanax horridus</i> (Devil's Club) Pei-Pei Liu, Mo Li, Ting-Guo Kang, De-Qiang Dou and David C Smith	1019
Triterpene Saponins from <i>Cyclamen persicum</i> Ghezala Mihci-Gaidi, David Pertuit, Tomofumi Miyamoto, Jean-François Mirjolet, Olivier Duchamp, Anne-Claire Mitaine-Offer and Marie-Aleth Lacaille-Dubois	1023
Cytotoxic Pentacyclic Triterpenoids from <i>Combretum oliviforme</i> Xiao-Peng Wu, Chang-Ri Han, Guang-Ying Chen, Yuan Yuan and Jian-Ying Xie	1027
Preparative Separation of Four Major Bufadienolides from the Chinese Traditional Medicine, Chansu, Using High-Speed Counter-Current Chromatography Xiu Lan Xin, Junying Liu, Xiao Chi Ma, Qing Wei, Li Lv, Chang Yuan Wang, Ji Hong Yao and Jian Cui	1031
Acetylcholinesterase and Butyrylcholinesterase Inhibitory Compounds from <i>Eschscholzia californica</i> (Papaveraceae) Lucie Cahliková, Kateřina Macáková, Jiří Kuneš, Milan Kurfürst, Lubomír Opletal, Josef Cvačka, Jakub Chlebek and Gerald Blunden	1035
In Vitro Testing for Genotoxicity of Indigo Naturalis Assessed by Micronucleus Test Luca Dominici, Barbara Cerbone, Milena Villarini, Cristina Fatigoni and Massimo Moretti	1039
Metabolites from <i>Withania aristata</i> with Potential Phytotoxic Activity Gabriel G. Llanos, Rosa M. Varela, Ignacio A. Jiménez, José M. G. Molinillo, Francisco A. Macías and Isabel L. Bazzocchi	1043
Bioassay-guided Isolation and Quantification of the α-Glucosidase Inhibitory Compound, Glycyrrhisoflavone, from <i>Glycyrrhiza uralensis</i> Wei Li, Songpei Li, Lin Lin, Hong Bai, Yinghua Wang, Hiroyoshi Kato, Yoshihisa Asada, Qingbo Zhang and Kazuo Koike	1049
Xanthones, Biflavanones and Triterpenes from <i>Pentadesma grandifolia</i> (Clusiaceae): Structural Determination and Bioactivity Grace Leontine Nwaboloun Djoufack, Karin M. Valant-Vetschera, Johann Schinnerl, Lothar Brecker, Eberhard Lorbeer and Wolfgang Robien	1055
Gmelinoside I, a New Flavonol Glycoside from <i>Limonium gmelinii</i> Zhanar A. Kozhamkulova, Mohamed M. Radwan, Galiya E. Zhusupova, Zharilkasin Zh. Abilov, Saniya N. Rahadilova and Samir A. Ross	1061
2-Arylbenzofuran Neolignans from the Bark of <i>Nectandra purpurascens</i> (Lauraceae) Jaime Rios-Motta and Eliseo Avella	1063

Continued inside backcover